Clin2
NCT06299891Possibly a fitRecruiting

Study of weight loss medication for youth with hypothalamic obesity

Hypothalamic ObesityHypothalamic TumorCraniopharyngioma

Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.

This study tests a combination of two medications, phentermine and topiramate, to see if they help young people with hypothalamic obesity lose weight safely. Hypothalamic obesity is rapid weight gain caused by injury to the hypothalamus, often from a brain tumor or its treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
24 people
Ages
6 years to 28 years
Study type
Interventional

Who can take part

  • You are between 6 and 28 years old.
  • You gained weight quickly after a brain tumor or its treatment.
  • You have obesity (BMI above the 95th percentile for your age and sex, or BMI over 30 for adults).
  • You have evidence of hypothalamus injury on an MRI, and it's been at least 6 months since your last tumor treatment.
  • You have been on a stable dose of any hormone replacement or appetite medications for at least 2 months.
  • If you are a female who has started your period, you must use effective birth control or have confirmed hormone issues that prevent pregnancy.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06239116Recruiting· Phase 1/Phase 2
RM-718 for obesity from hypothalamus injury or Prader-Willi syndrome

This study tests a new medicine called RM-718 for people with severe obesity linked to a specific brain pathway (MC4R). It may help if your obesity is due to a brain injury or tumor affecting the hypothalamus, or if you have Prader-Willi syndrome.

Birmingham, Alabama
NCT06901245Recruiting· Phase 4
Tirzepatide for young adults with obesity

This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.

Saint Paul, Minnesota
NCT06905626Not yet recruiting· Phase 3
Preventing weight gain in young adults

This study tests a program to help young adults with a family history of obesity avoid gaining weight. It involves checking if certain health conditions or medications would make the program unsafe.

NCT07282340Recruiting· Phase 2
Phentermine for weight loss in teens

This study tests a medicine called phentermine to help teens ages 12 to 17 with obesity lose weight. It will check if the medicine is safe and works well for teenagers.

Baton Rouge, Louisiana
NCT07790913Not yet recruiting· Phase 2
Weight loss medication for teens after leukemia or lymphoma

This trial tests a combination pill (phentermine and topiramate) to help teens and young adults who are overweight after finishing cancer treatment. The goal is to improve metabolic health and manage weight in remission.

Memphis, Tennessee
NCT06672549Recruiting· Phase 3
Weight loss medication study for children with obesity

This trial tests a medication for children and teens with obesity or overweight who have not been able to lose enough weight with diet and exercise alone. It aims to see if a new treatment can help them safely lose weight and improve related health problems.

Tucson, Arizona

Hear when a new Hypothalamic Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.